-
Rheumatology International Feb 2017This study aims to estimate the prevalence of serositis and identify risk factors for serositis in a large cohort of systemic lupus erythematosus (SLE) patients. A...
This study aims to estimate the prevalence of serositis and identify risk factors for serositis in a large cohort of systemic lupus erythematosus (SLE) patients. A cross-sectional study was conducted based on the medical records of patients hospitalized with SLE at the First Affiliated Hospital of Anhui Medical University and Anhui Provincial Hospital. Patients were diagnosed with serositis when they presented with symptoms and signs of pleuritis or/and pericarditis. We explored factors associated with the generation and quantity of serositis by using binary and ordinal logistic regression analysis. Among the 1668 lupus patients, 298 have serositis. Active lupus disease, fever (≥38 °C) and high D-dimer were all significantly associated with the generation and quantity of serositis. Male gender was independent significant risk factor for pleuritis but not for pericarditis, while low complement C4 and high erythrocyte sedimentation rate (ESR) were risk factors for pericarditis rather than for pleuritis. The possible prevalence of serositis in patients with SLE was 17.9%. The significant associations of active lupus disease, fever (≥38 °C) and high D-dimer with serositis suggest that higher disease activity and hypercoagulability may both contribute to the generation and development of serositis in SLE. The risk factors for pleuritis and pericarditis in SLE are similar but not identical.
Topics: Adult; Cross-Sectional Studies; Female; Fibrin Fibrinogen Degradation Products; Humans; Lupus Erythematosus, Systemic; Male; Prevalence; Risk Factors; Serositis
PubMed: 27999942
DOI: 10.1007/s00296-016-3630-0 -
Cancer Immunology, Immunotherapy : CII Dec 2022As immune checkpoint inhibitors (ICI) are increasingly being used due to effectiveness in various tumor entities, rare side effects occur more frequently. Pericardial...
BACKGROUND
As immune checkpoint inhibitors (ICI) are increasingly being used due to effectiveness in various tumor entities, rare side effects occur more frequently. Pericardial effusion has been reported in patients with advanced non-small cell lung cancer (NSCLC) after or under treatment with immune checkpoint inhibitors. However, knowledge about serositis and edemas induced by checkpoint inhibitors in other tumor entities is scarce.
METHODS AND RESULTS
Four cases with sudden onset of checkpoint inhibitor induced serositis (irSerositis) are presented including one patient with metastatic cervical cancer, two with metastatic melanoma and one with non-small cell lung cancer (NSCLC). In all cases treatment with steroids was successful in the beginning, but did not lead to complete recovery of the patients. All patients required multiple punctures. Three of the patients presented with additional peripheral edema; in one patient only the lower extremities were affected, whereas the entire body, even face and eyelids were involved in the other patients. In all patients serositis was accompanied by other immune-related adverse events (irAEs).
CONCLUSION
ICI-induced serositis and effusions are complex to diagnose and treat and might be underdiagnosed. For differentiation from malignant serositis pathology of the punctured fluid can be helpful (lymphocytes vs. malignant cells). Identifying irSerositis as early as possible is essential since steroids can improve symptoms.
Topics: Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Serositis; Immune Checkpoint Inhibitors; Edema
PubMed: 35576074
DOI: 10.1007/s00262-022-03211-7 -
Clinical and Experimental Rheumatology Sep 2022Adult-onset Still's disease (AOSD) is increasingly viewed as autoinflammatory disease associated with the so-called inflammasomopathy. Proinflammatory cytokines, such as...
OBJECTIVES
Adult-onset Still's disease (AOSD) is increasingly viewed as autoinflammatory disease associated with the so-called inflammasomopathy. Proinflammatory cytokines, such as IL-18 and IL-1β, processed through the inflammasome machinery, play an important role in the pathogenesis of AOSD. AOSD is heterogenous, therefore there are two subtypes of the disease, systemic and articular, which probably imply different approaches for the treatment. Over 20% of patients with systemic AOSD have serositis. Recently, colchicine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) has become the "gold standard" for recurrent pericarditis treatment. However, data on this combination therapy in AOSD are scarce.
METHODS
In this retrospective case series study, we assessed the medical history of 20 patients with a systemic form of AOSD. All patients had pericarditis and received а combination of NSAIDs (in most cases ibuprofen 600-800 mg x3 daily) and colchicine (1 mg daily) for treatment.
RESULTS
13/20 (65%) of patients responded to this combination of anti-inflammatory drugs. Of note, not only pericarditis, but also other manifestations were improved such as arthritis, rash, hepatomegaly, acute phase reactants, and abnormal liver tests.
CONCLUSIONS
The low cost, safety and wide availability of such therapy make this option relevant and determine the need for further study.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Humans; Pericarditis; Retrospective Studies; Serositis; Still's Disease, Adult-Onset
PubMed: 35084308
DOI: 10.55563/clinexprheumatol/1o41c8 -
Prensa Medica Argentina Jan 1947
Topics: Serositis
PubMed: 20239317
DOI: No ID Found -
Prensa Medica Argentina Aug 1968
Topics: Adult; Diagnosis, Differential; Etiocholanolone; Female; Humans; Male; Serositis
PubMed: 5709491
DOI: No ID Found -
The New Zealand Medical Journal Oct 2003
Topics: Acute Disease; Aged; Antipsychotic Agents; Clozapine; Humans; Male; Pericardial Effusion; Pleural Effusion; Psychotic Disorders; Serositis
PubMed: 14583809
DOI: No ID Found -
Journal of Hospital Medicine Feb 2015
Topics: Adult; Health Expenditures; Humans; Lupus Erythematosus, Systemic; Male; Serositis
PubMed: 25537658
DOI: 10.1002/jhm.2304 -
Transplantation Proceedings 2017Although everolimus, a mammalian target of rapamycin inhibitor, has been used as a potent immunosuppressive agent in organ transplantation, data regarding its adverse...
Although everolimus, a mammalian target of rapamycin inhibitor, has been used as a potent immunosuppressive agent in organ transplantation, data regarding its adverse effect profile compared with that of sirolimus in clinical circumstances are limited. A 50-year-old man who underwent simultaneous liver and kidney transplantation 14 months previously was admitted with large pleural effusion, pericardial effusion, and ascites. Laboratory findings and cultures for possible infectious causes were all negative. Pericardial window surgery with drainage of the pericardial fluid was performed on day 3. Pleural and pericardial biopsy revealed non-specific inflammation without evidence of malignant cells. Everolimus was discontinued and replaced by mycophenolate mofetil on day 4. Significant clinical improvement was observed after discontinuation of everolimus, and follow-up echocardiography and chest radiography showed no recurrence of the pericardial or pleural effusion after discharge.
Topics: Ascites; Diabetic Nephropathies; Drainage; Echocardiography; Everolimus; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Pericardial Effusion; Pericarditis; Pleural Effusion; Pleurisy; Prednisolone; Serositis; Tacrolimus; Tomography, X-Ray Computed
PubMed: 28104132
DOI: 10.1016/j.transproceed.2016.11.026 -
Revue Medicale de La Suisse Romande 1945
Topics: Humans; Pericarditis; Serositis
PubMed: 21065621
DOI: No ID Found -
The American Journal of Pathology 1955
Topics: Animals; Birds; Communicable Diseases; Disease; Ducks; Poultry; Serositis
PubMed: 14376507
DOI: No ID Found